CTRI/2011/05/001767
Not yet recruiting
Phase 4
Assessment of Interleukin 1β levels and clinical effects of curcumin gel in an experimental gingivitis model. A randomized double blind placebo controlled clinical trial - NI
Shaju Jacob P0 sites20 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Shaju Jacob P
- Enrollment
- 20
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Systemically healthy adults between 20 and 24 years of age with healthy periodontium (no sites with 2mm of probing depth.
Exclusion Criteria
- •Pregnancy, on antibiotics, on antiinflammatory drugs.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A single centre phase II study of Interleukin 1 receptor antagonist in the treatment of severe Traumatic Brain Injury - Interleukin-1 Receptor Antagonist in Severe Traumatic Brain InjuryEUCTR2005-005707-42-GBCambridge University Hospitals NHS Foundation Trust and University of Cambridge20
Not yet recruiting
Not Applicable
Relationship between levels of Interleukin-1a in gum fluid and the development of root resorption after dental injury.CTRI/2024/07/070145nithiyalakshmi kanagaraj
Not yet recruiting
Not Applicable
A clinical study to evaluate the levels of inflammatory markers around mini-implants which are used during orthodontic treatment.CTRI/2018/05/013863Bianca B Rodrigues
Active, not recruiting
Phase 1
Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes - MRC-ILA-HEART studyWe wish to investigate Acute coronary syndromes (ACS). These are caused by blockages in the main arteries that supply the heart as a result of a process called atherosclerosis. These blockages prevent blood flow down the artery and therefore prevent the heart muscle getting the blood and oxygen that it needs to survive and function. They account for 15% of all deaths in the UK and are associated with considerable long term consequences among survivors.MedDRA version: 8.1 Level: PT Classification code 10051592 Term: Acute coronary syndromeEUCTR2006-001767-31-GBniversity of Sheffield186
Completed
Phase 2
Interleukin-1 receptor antagonist in severe traumatic brain injuryTraumatic brain injuryInjury, Occupational Diseases, PoisoningIntracranial injuryISRCTN88597330Cambridge University Hospitals NHS Foundation Trust (UK)26